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Abstract Machado-Joseph disease (MJD) or spinocerebellar
ataxia type 3 (SCA3) is a neurodegenerative disease currently
with no treatment. We describe a novel mouse model of MJD
which expresses mutant human ataxin-3 at near endogenous
levels and manifests MJD-like motor symptoms that appear
gradually and progress over time. CMVMJD135 mice show
ataxin-3 intranuclear inclusions in the CNS and neurodegen-
erative changes in key disease regions, such as the pontine and
dentate nuclei. Hsp90 inhibition has shown promising out-
comes in some neurodegenerative diseases, but nothing is
known about its effects in MJD. Chronic treatment of
CMVMJD mice with Hsp90 inhibitor 17-DMAG resulted in
a delay in the progression of their motor coordination deficits
and, at 22 and 24 weeks of age, was able to rescue the
uncoordination phenotype to wild-type levels; in parallel, a
reduction in neuropathology was observed in treated animals.
We observed limited induction of heat-shock proteins with
treatment, but found evidence that 17-DMAG may be acting
through autophagy, as LC3-II (both at mRNA and protein
levels) and beclin-1 were induced in the brain of treated
animals. This resulted in decreased levels of the mutant
ataxin-3 and reduced intranuclear aggregation of this protein.
Our data validate this novel mouse model as a relevant tool for
the study of MJD pathogenesis and for pre-clinical studies,
and show that Hsp90 inhibition is a promising therapeutic
strategy for MJD.
Keywords Polyglutamine . animal models . ataxia .
behavior . therapy . autophagy.
Introduction
Machado-Joseph disease (MJD), also known as
spinocerebellar ataxia type 3 (SCA3), is caused by a CAG
repeat expansion (>55) [1] in the protein coding region of the
ATXN3 gene, located in chromosome 14q32.1 and encoding
the protein ataxin-3. The main clinical features of MJD are
ataxia and ophthalmoplegia, which can be associated to a
variable degree with peripheral amyotrophy, intention
fasciculation-like movements of facial and lingual muscles,
rigidity, spasticity, dystonia and palpebral retraction, leading
to the appearance of bulging eyes [2]. Ataxin-3 harboring the
expanded polyQ tract has a strong tendency for aggregation,
leading to the formation of inclusions in the nucleus and
cytoplasm of neuronal cells, including axonal tracts [3, 4],
the pathogenic relevance of which remains unclear.
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Molecular chaperones are crucial for the maintenance of
native protein conformation, and recent research has shown
that defective chaperone action may have pathogenic conse-
quences [5, 6]. Several studies demonstrated the involvement
of the heat shock proteins in MJD [7–10]; co-localization of
Hsp70, Hsp40 and Hsp90, but not other chaperones (Hsp27,
Hsp60 and Hsp110) with aggregates formed bymutant ataxin-
3 has been described, which might result in a depletion of
these protective molecules [7, 9]. In order to promote the
correct refolding of the pathogenic protein(s) and to reduce
the formation of toxic aggregated forms, the use of com-
pounds that promote increased expression of heat shock pro-
teins (HSPs), leading to improved protein folding and/or
clearance of the mutant protein by the ubiquitin proteasome
system or through autophagy, has been proposed [11, 12].
Hsp90, by itself and/or associated with multichaperone com-
plexes, is a major repressor of HSF-1 acting in a feedback
regulation mechanism [13]. Pharmacologic inactivation of
Hsp90 leads to the overexpression of several molecular chap-
erones, activating the heat-shock response (HSR) via the
persistence of HSF-1 action [13, 14]. Potent Hsp90 inhibitors,
such as 17-AAG or 17-DMAG, have been shown to reduce
aggregate load and toxicity in cell, fly, nematode and mouse
models of several neurodegenerative diseases, dependently on
HSF-1 [15–20]. Concerning polyQ diseases, these two com-
pounds have been shown to have beneficial effects only for
SBMA [19–21]. Despite its high potency, 17-AAG showed
poor solubility and stability and demonstrated moderate tox-
icity in several clinical trials [22]. In contrast, 17-DMAG is a
more potent analog of 17-AAG [23], is more water soluble
than 17-AAG and can be administered orally [24], which
could be advantageous for clinical purposes.
Although mouse models have been a remarkable tool in
human disease research, several criteria have to be achieved in
order to validate a genetically manipulated mouse as a model
of a disease [25]. Therapeutic trials need to be performed in
animal models showing significant similarities to the human
diseases, in order to better evaluate the therapeutic benefit of a
specific compound. Although several transgenic mouse
models have been generated for the study of MJD, it has been
difficult to find in one single model the main features of this
disorder (reviewed in [26]).
In this work, we generated a new transgenic mouse model
expressing ATXN3 with 135 glutamines under the control of
the CMV promoter. These mice develop a progressive neuro-
logical disease overlapping with the core clinical features of
MJD and show relevant neuropathology as well as ubiquitin-
positive ataxin-3 intranuclear inclusions in regions of the brain
known to be involved inMJD, including the pontine and deep
cerebellar nuclei. We used this model in a pre-clinical trial to
validate Hsp90 inhibition as a therapeutic strategy for MJD,
with encouraging results that suggest that this approach
should be pursued.
Results
CMVMJD135 Mice Express the Expanded Human Ataxin-3
in the CNS
We have generated transgenic mice expressing the ATXN3c
cDNA variant of the ATXN3 gene carrying a repeat tract with
the sequence (CAG)2CAAAAGCAGCAA(CAG)129, coding
for 135 glutamines, under the regulation of the CMV promoter
(Fig. 1A). Transgene mRNA quantification demonstrated that
one lineage (hereafter designated CMVMJD135), expressed the
human ATXN3 protein in the brain (Fig. 1B). This lineage,
possessing two copies of the transgene, expressed the human
ATXN3 mRNA at near-endogenous levels in the cerebellum,
brainstem, forebrain and spinal cord (Fig. 1C). When breeding
these animals we observed intergenerational CAG repeat length
variation, mostly towards contraction (Supplementary Fig. 1)
(maternal meioses (n=24): mean=−1.46±2.74; range=[−7, +4];
paternal meioses (n=42): mean=−0,71±1,61; range=[−5, +1]).
We chose to study animals with repeat lengths over 129. All the
comparisons for the genotype factor were performed between
CMVMJD135 mice and wild-type littermates since it has been
previously shown that transgenic mice expressing human
ataxin-3 carrying a normal CAG repeat tract did not display
any differences in the phenotype or neuropathology in compar-
ison with wild-type (wt) [27–30]. In addition, our previous data
have shown that even expression of ataxin-3 with 83 glutamines
under the CMV promoter caused no phenotype change [31].
CMVMJD135 Transgenic Mice Display Progressive
Neurological Deficits
At 4 weeks of age, transgenic and control littermates were
indistinguishable in their home cage; however, at 16 weeks of
age transgenic animals started to present a visibly abnormal
gait and at 40 weeks of age they showed an unhealthy appear-
ance, an abnormal body posture, limb clasping and limb tonus
deficit (Fig. 1D).
Female CMVMJD135 transgenic and control mice gained
weight at a similar rate until 19 weeks of age (Fig. 1E);
however, transgenic males showed a significantly lower body
weight gain compared with control males at 19 weeks of age,
and since this age, all transgenic animals demonstrated a
decline in body weight, whereas their wt littermates continued
to gain weight until 40 weeks of age (male: genotype x age,
F2,61=35.067, p<0.000; female: genotype x age, F2,61=5.211,
p=0.008).
In the balance beam test, CMVMJD135 mice showed a
significantly worse performance already at 10 weeks of age
traversing the medium square beam (male: genotype, F1,40=
30.845, p=2×10-6, age, F1,40=6.356, p=0.014; female: geno-
type, F1,44=10.754, p=0.002) (Fig. 2B), as well as the medi-
um (male: genotype, F1,34=22.023, p=4.3×10
-5; female:
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genotype, F1,37=4.859, p=0.034) (Fig. 2D) and the small
round beams (male: genotype, F1,31=18.486, p=1.58×10
-4;
female: genotype, F1,34=11.487, p=0.002, age, F1,34=5.618,
p=0.024) (Fig. 2E). With disease progression, CMVMJD135
mice demonstrated a higher frequency of foot slips and a
flattened body posture in the beams. By 40 weeks of age,
transgenic mice failed to maintain balance on the beams and
fell off.
Footprint patterns of wt (41 weeks of age) and
CMVMJD135 transgenic mice at 14, 28 and 41 weeks of
age are illustrated in Fig. 3A. Dragging of the feet was
observed in transgenic animals already at 14 weeks of age,
progressing through age and becoming increasingly more
severe (41 weeks: p=2.44×10-4) (Fig. 3B). Additionally, be-
ginning at 16 weeks of age, transgenic mice displayed a
reduced paw overlap when compared with control animals,
indicating an altered uniformity of step alternation (genotype,
F1,11=5.184, p=0.044) (Fig. 3C) as well as a significant
decrease in the stride length (genotype, F1,11=36.086,
p=8.8×10-5) (Fig. 3D).
CMVMJD135 mice swam significantly slower than con-
trol littermates at 22–25 weeks of age (genotype, F1,21=
17.927, p=3.71×10-4) and more so at 40 weeks (genotype,
F1,15=42.466, p=1.0×10
-5) (Fig. 4A). In addition, they
displayed abnormalities in their swimming movements,
adopting a twisted posture, and kicked in an uncoordinated
Fig. 1 Generation of a transgenic mouse model of MJD carrying the
expandedATXN3with 135 CAGs. (A) Schematic diagram of the plasmid
CMVMJDAT3Q135_1.5 used for the generation of cDNA MJD trans-
genic mice. (B) Western blot anti-ATXN3 in different CNS regions
(cerebellum, forebrain and brainstem) of CMVMJD135 mice with 14–
16 weeks of age. In all lanes, the endogenous mouse ataxin-3 (Atxn3) is
detected at about 42 kDa. An approximately 80-kDa protein correspond-
ing to expandedATXN3 is detected in transgenic animal lysates. (C) qRT-
PCR analysis of human ATXN3 and murine Atxn3 mRNA expression
levels. Values are presented as mean ± SEM (n=4). (D) CMVMJD135
mice at 40 weeks of age presenting body posture deficit with lower pelvic
elevation and hunchback (2), limb clasping (4) and reduced hindlimb
tonus (6) in comparison with wt animals (1,3,5). (E) Assessment of body
weight with age (n=11–12 for each group). Asterisks indicate significant
differences between wt control and CMVMJD135 transgenic mice.
*p<0.05, **p<0.01, ***p<0.001
17-DMAG Improves MJD Mouse Phenotype
FOR APPROVAL
manner with both hind- and forelimbs. In the rotarod para-
digm, significant differences were observed from the age of 20
weeks (genotype, F1,21=4.879, p=0.038) (Fig. 4B). At 40
weeks of age, transgenic animals showed a dramatic deterio-
ration in their rotarod performance compared with littermate
controls, both in the accelerating rod (genotype,F1,17=20.234,
p=3.17×10-4) and at constant speeds (8 rpm: p=0.004;
15 rpm: p=0.002; 20 rpm: p=0.003; 24 rpm: p=0.002)
(Fig. 4C).
At the first age of assessment with the SHIRPA protocol
(7 weeks) CMVMJD135 transgenic mice revealed significant
differences in performance in the hanging wire grip test, that
became worse with age (male: genotype x age, F1,42=30.331,
p=2.0×10-6; female: genotype x age, F1,41=36.955,
p<0.000) (Fig. 5A). At 19 weeks of age, a significant
percentage of transgenic animals developed loss of hindlimb
tonus resistance (male: p=1.07×10-4; female: p=0.002)
(Fig. 5B), a decrease in forelimb strength (male: p=0.003;
female: p=0.006) (Fig. 5C) and hindlimb clasping (male:
p=1.07×10-4; female: p=0.006) (Fig. 5D). Furthermore, 40-
week-old animals demonstrated a dramatic deterioration of
the neurological symptoms observed at 19 weeks of age in
the SHIRPA protocol, namely, the loss of hindlimb tonus,
the tremors and the decreased locomotor and exploratory
activity, among others (Supplementary Fig. 2A–D). From 40
weeks of age onwards, most CMVMJD135 mice were not
able to traverse the beams or stay in the rotarod and their
footprinting pattern was difficult to measure due to the
severe dragging, which led us to halt the phenotype
evaluation.
Fig. 2 Body balance impairment
in CMVMJD135 mice. Balance
beam test performance of wt and
transgenic animals using square
(A,B) and round beams (C–E) is
depicted at 10 and 22 weeks of
age. Values are presented as
mean ± SEM (n=8–13 for each
genotype and gender). *p<0.05,
**p<0.01, ***p<0.001
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A group of wt (n=9) and transgenic animals (n=13) were
followed through life until they had to be sacrificed due to
established humane endpoints (93 weeks of age). Although
transgenic mice showed a progressive deterioration of the
motor phenotype, no differences were observed in survival
rate between both genotypes until this age, in the laboratory
conditions used, which included lowering the food to an ac-
cessible level and hydrating it at ages when transgenic animals
had difficulty reaching the food and drink compartments.
For cognitive assessment, the Morris Water Maze test was
performed at 10 weeks of age, before the motor symptoms
would interfere excessively with testing, and no differences
were found (Supplementary Fig. 2E,F).
CMVMJD135 Mice Exhibit Reduced Brain Weight, Reduced
Volume and Total Cell Number in Pontine Nuclei
and Intranuclear Ataxin-3 Inclusions
The total brain weight of CMVMJD135 mice was slightly
reduced (5 %) in comparison with control littermates at late
stages of the disease (42–43 weeks) (p=2.74×10-4) (Fig. 6A).
However, we did not observe differences in brain weight in
animals sacrificed at 20 weeks of age, suggesting that the
motor phenotype begins before marked neuronal loss. Stereo-
logical evaluation of CMVMJD135 mice brains at 60 weeks
of age revealed a significantly reduced volume as well as a
decrease in total cell number in pontine nuclei indicating
neuronal demise in this region, known to be affected in MJD
(Fig. 6B). Interestingly, transgenic mice showed a significant
volume reduction without cell loss in the dentate nuclei. In
contrast, no differences were found in the locus coeruleus and
in the substantia nigra (SN), although hyperchromatic cells
and astrogliosis were observed in SN (Fig. 6C; Supplementary
Fig. 3).
Immunohistochemistry showed the presence of ataxin-3
inclusions in the nucleus of neuronal cells in different regions
of the CNS of CMVMJD135 mice at 20–35 weeks of age
(Fig. 6C) including the pontine nuclei, reticulotegmental nu-
cleus of the pons, spinal cord neurons, the facial nuclei,
anterior olfactory nuclei, ventral tenia tecta, inferior olive,
Fig. 3 Abnormal footprint pattern in transgenic mice. (A) Representative
walking footprint patterns of 14-, 28- and 41-week-old CMVMJD135
mice. Qualitatively, the patterns generated clearly differ, showing that
transgenic mice display foot-dragging. At late stages CMVMJD135 mice
also demonstrate shorter strides and an irregular left–right step pattern as
compared with the wt control mice. (B) Quantitative analysis of foot-
dragging. Quantitative analysis of the footprint patterns of wt and trans-
genic mice, based on measurements of (C) distance between front and
hind footprint overlap and (D) stride length through age. Values are
presented as mean ± SEM (n=7 and 10 for wt and transgenic, respectively).
*p<0.05, **p<0.01, ***p<0.001
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the dentate nuclei, locus coeruleus and the cuneate nuclei. The
evaluation of cell morphology by cresyl violet staining at 24
weeks of age showed an increased abundance of seemingly
atrophic and hyperchromatic neurons in the pontine nuclei of
CMVMJD135 mice (Fig. 6C,g–j).
17-DMAG Chronic Treatment Improved Several Features
of the Motor Phenotype Observed in CMVMJD135 Mice
Given previous results suggesting that Hsp90 inhibition could
be a useful therapeutic approach for polyQ disease, our own
finding with 17-DMAG in a nematode model of MJD [32],
and the lack of studies in vertebrate models of this disorder,
we tested the effect of 17-DMAG in the CMVMJD135
mouse. All analyses in this pre-clinical trial were performed
using male mice.
A pilot study was performed in wt animals in order to
determine the effective dose of 17-DMAG which induces
Hsp70 in the brain. Previous studies have shown increased
oral availability of 17-DMAG in comparison with 17-AAG;
however, above 10 mg/kg 17-DMAG has been described to
be toxic in mice [33]. It has also been demonstrated that i.p.
17-DMAG administration leads to a better bioavailability than
the oral route [24]. In our dose–response study using three i.p.
injections per week on alternate days, with 17-DMAG at 5, 10
or 25 mg/kg, we observed that, 12 hours post-last injection,
only with the dose of 25 mg/kg was the expression of Hsp-70
significantly induced in the brain, this dosage being thus
selected for the chronic therapeutic study (Supplementary
Fig. 4). With systemic administration of this dosage, the
concentration of 17-DMAG in the brain 1 hour after treatment
was 42 ng/g (drug quantity/brain weight) with a plasma/brain
ration of 0,2.
Fig. 4 Motor incoordination on the rotarod and in the swimming tank in
CMVMJD135 mice. (A) 22–25- and 40-week-old wt and CMVMJD135
male mice (n=7–15) were tested for motor coordination in the swimming
tank, by assessing the latency to swim over a 60-cm distance to a visible
escape platform. Transgenic mice displayed swimming impairments giv-
en by a significant increase in the time spent to cross the 60-cm distance.
Rotarod analysis of CMVMJD135 and wt animals were tested in (B) an
accelerating rod (4–40 rpm) and (C) at constant speeds. The mean±SEM
of the latency to fall at each speed level was recorded. Rotarod deficit was
present at 20 weeks of age and older (shown for 40 weeks);
CMVMJD135 transgenic mice displayed a progressive decline in perfor-
mance on the rotarod with increasing rotation speed. *p<0.05, **p<0.01,
***p<0.001
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In the therapeutic assay, we used four groups of animals:
17-DMAG- and vehicle-treated wt (n=10; n=10, respectively)
and CMVMJD135 animals (n=10; n=12, respectively). In the
motor swimming test, 17-DMAG treatment had a highly ben-
eficial effect, being able to improve the phenotype of the
transgenic animals almost to the performance level of wt
animals at 16, 22 and 24 weeks of age (genotype x treatment,
F1,38=19.912, p=0.00007); this effect was lost at 30 weeks of
age (Fig. 7A). 17-DMAG treatment also had a positive effect
in the rotarod performance of CMVMJD135 animals, which
was comparable to that of wt animals at 22 weeks of age
(15 rpm: genotype x treatment, F1,33=6.378, p=0.017); this
Fig. 5 Phenotype of CMVMJD135 mice detected in the SHIRPA pro-
tocol. (A) Strength and fine motor coordination evaluation in the hanging
wire grip test, measured by the latency to fall off the grid. Values are
presented as mean ± SEM (n=11–12 for each group). (B) At 19 weeks of
age animals demonstrated hindlimb tonus alterations, (C) a decrease in
forelimb grip strength and (D) a higher percentage of animals displaying
clasping of the hindlimbs when compared to controls. Values are present-
ed as percentage of animals with different scores in the SHIRPA protocol
(n=11–12 for each group). *p<0.05, **p<0.01, ***p<0.001
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effect was no longer statistically significant at 24 and 30 weeks
of age (Fig. 7B). At 22 and 24 weeks of age 17-DMAG-treated
CMVMJD135 mice had a better performance in the balance
beam test (Fig. 7C; Medium square 24 weeks—genotype:
F1,37=6.228, p=0.017; treatment: F1,37=6.903, p=0.012.
Small circle 22 weeks—genotype: F1,37=7.45, p=0.01;
Fig. 6 Neuropathology of CMVMJD135 mice. (A) Brain weight analy-
sis at 42–43 weeks of age of wt (n=5) and CMVMJD135 male mice (n=
4). (B) Volume and total cell number quantification in different brain
regions of transgenic (n=9) and control (n=5) male animals using stereo-
logical methods. (C) Anti-ataxin-3 immunohistochemistry (rabbit anti-
MJD1.1) of wt (a-c) and CMVMJD135 mice (d-f) at approximately 20–
35 weeks of age. CMVMJD135 mice exhibited nuclear and cytoplasmic
inclusions positive for ataxin-3 in different regions of the CNS, namely,
pontine nuclei (d), reticulotegmetal nucleus of pons (e) and spinal cord
neurons (f); Cresyl violet brain sections in the pontine nuclei of wt (g) and
in CMVMJD135 (i) mice. Higher magnification of neuronal cells in the
wt (h) and transgenic mice (j). Images are representative of the results
obtained for six animals per genotype, three each female and male. Scale
bar: 20 μm
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treatment: F1,37=10.385, p=0.003. Small circle 24weeks—
genotype: F1,36=8.50, p=0.006; treatment: F1,36=7.346, p=
0.01), which was not maintained at 30 weeks of age, suggest-
ing that 17-DMAG treatment is delaying the manifestation of
loss of balance in these animals. Moreover, 17-DMAG was
able to delay the onset and progression of the foot-dragging
phenotype, since at any age the percentage of CMVMJD135
animals treated with 17-DMAG showing foot-dragging was
less than in those not receiving treatment (p<0.05) (Fig. 7D).
In summary, 17-DMAG chronic treatment was able to delay
the motor deficits in the rotarod, motor swimming and balance
beam test by approximately 8 weeks, which represents approx-
imately 9 % of the median C57Bl/6 normal lifespan [34]
(600 days), and to a lesser extent the foot-dragging (6 weeks,
7 % of the lifespan).
17-DMAG treatment failed to ameliorate other manifesta-
tions of the disease evaluated in the SHIRPA protocol, name-
ly, those more related to weakness/hypotonia (hanging wire,
hindlimb tonus), tremors and abnormal reflexes (limb
clasping). Although we did not detect any improvement in
the hanging wire test, in the total number of rears and body
weight, the sample size we used (n=10–12) would be suffi-
cient to detect an improvement of 50 % at several time points
(see Supplementary Table). For the number of squares trav-
elled in the arena, the required sample size for the observed
mean difference to be significant would be much larger than
the one we used (see Supplementary Table).
17-DMAG Treatment Reduces Neuropathology in the CNS
of CMVMJD135 Mice
Transgenic vehicle-treated animals demonstrated the presence
of shrunken and morphologically abnormal cells in the ponti-
ne nuclei. In contrast, 17-DMAG treated animals showed
normal cell morphology, shrunken cells being almost unde-
tectable in this brain region at 30 and 16 weeks of age
(Supplementary Fig. 5). Quantification of the ataxin-3 nuclear
inclusions present in the pontine nuclei of CMVMJD135 mice
revealed a significant reduction of the number of cells con-
taining these inclusions, also reflected in a reduced number of
inclusions per area, in 17-DMAG-treated transgenic animals
when compared to vehicle-treated ones (p=0.009) (Fig. 8A).
Mutant Ataxin-3 Levels are Reduced Through Autophagy
in 17-DMAG-Treated CMVMJD135 Mice
No differences were found in ataxin-3 expression at mRNA
level in the brainstem between the treatment groups, which
allow us to conclude that 17-DMAG treatment is not affecting
expression of ataxin-3 at the transcription level (Fig. 8B).
Interestingly, however, the protein levels of mutant human
ataxin-3 in the brainstem were dramatically reduced in 17-
DMAG-treated animals at 16 (p=0.033) and 30 weeks of age
(p=0.019), suggesting that this treatment is promoting mutant
ataxin-3 degradation rather than refolding (Fig. 8C).
In an attempt to dissect the mechanism of action of the drug
we analysed the levels of molecular chaperones in treated
animals. Unexpectedly, at 20 weeks, mRNA expression levels
of molecular chaperones Hsp-70 and −40 were not signifi-
cantly increased upon 17-DMAG treatment in transgenic
mice, while there was a trend towards increase in the controls
(Fig. 9A). Hsp70 quantification in the forebrain at 16 and 30
weeks of age in CMVMJD135 mice demonstrated that chron-
ic treatment with 17-DMAG led to a statistically non-
significant trend towards increase in Hsp70 expression in this
brain region in transgenic mice at 16 weeks of age, whereas at
30 weeks the opposite trend was present (Fig. 9B). These
results suggest that HSR induction by chronic administration
of 17-DMAG at 25mg/kgmay be compromised in the disease
state, particularly at later stages. Since it was previously
shown that 17-AAG and its analogue 17-DMAG are able to
activate macroautophagy in different model systems [35–37],
we also assessed activation of this pathway. We observed an
increase in the beclin-1 protein levels in the brainstem of 16-
and 30-week-old mice and of the LC3-II/LC3-I ratio at 30
weeks of age, after chronic 17-DMAG treatment (p=0.008,
p=0.017, respectively) in transgenic mice but not in controls,
confirming the specificity of this activation (Fig. 9C,D).
Discussion
The pathogenic mechanism of MJD, as well as of other polyQ
disorders, is not well understood, and these disorders remain
incurable to date. In this work, we have generated a new
transgenic mouse model expressing at near the same cDNA
variant of ataxin- 3 as in our previous CMVMJD94 model,
ATXN3c- which corresponds to the most predominant variant
of the protein in the brain [38], but with an increased number
of glutamine residues (135Q). Moreover, we tested a potent
Hsp90 inhibitor, 17-DMAG, that was able to improve the
motor phenotype and the neuropathological features of
CMVMJD135 mice.
Our results show that the CMVMJD135 mouse is a pow-
erful model for pre-clinical trials in MJD. The behavioral
evaluation of CMVMJD135 mice revealed the presence of
several phenotypic abnormalities that gradually appear and
progress during a lifespan of over one and a half years,
namely, balance and motor coordination deficits, loss of limb
strength, decreased locomotor and exploratory activity, abnor-
mal gait and tremors, with many parameters assessable by
objective tests. The first sign of neurological disease in the
CMVMJD135 model was the presence of balance and grip
abnormalities at 6 weeks of age. Cerebellar ataxia is one of the
first clinical manifestations seen inMJD patients, and is due to
unsteadiness or impaired balance. Although behavioral
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alterations suggestive of loss of coordination in CMVMJD135
mice were observed at 4 and 8 weeks of age, at these ages
animals were indistinguishable from their wt littermates by
simple observation in their home cage. At 16 weeks of age,
however, signs of neurological abnormality were already ob-
servable in CMVMJD135 mice in their home cage, in partic-
ular a clearly abnormal gait. The footprinting pattern evalua-
tion of CMVMJD135 mice clearly demonstrated foot-
Silva-Fernandes et al.
FOR APPROVAL
dragging and, at later stages of the disease, a shortened step
length and a decrease in the hind/ frontlimb overlap. Trans-
genic animals also showed a significant deficit in the acceler-
ating rod at 20 weeks of age, which was further aggravated at
40 weeks of age, in the constant and accelerating rod. In the
motor swimming test, the abnormal posture and inappropriate
kicking movements exhibited by CMVMJD135 contrasted
markedly with the coordinated synchronized paddling move-
ments shown by wt mice.
The analysis of CAG repeat number through the genera-
tions of CMVMJD135 mice revealed that CAG tract length
varied in approximately 54–79 % of the transmissions, fre-
quently towards contractions. The genescan profile of the
CAG tract obtained from mouse tail revealed that somatic
mosaicism was also present. Thus, our new model seems to
replicate this feature of the human disease as well.
The histological evaluation of CMVMJD135 mouse brains
frequently revealed abnormal cell morphology in the pontine
nuclei as well as gliosis in the substantia nigra at clearly
symptomatic ages (24 weeks of age). The stereological anal-
ysis of pontine nuclei of CMVMJD135 brain at late stages
(60 weeks of age) revealed a reduced volume and total cell
number in this region and reduced volume in the dentate
nuclei, two regions of high involvement in human patients.
Moreover, we observed a total brain weight decrease, but only
at late stages of the disease (42–43 weeks of age), which
supports the hypothesis that major cell loss only occurs at
these advanced stages. These results suggest that the early
motor phenotype observed in our model is mostly attributable
to dysfunction of the brain regions affected in MJD, clearly
preceding neuronal cell death. In order to validate this hypoth-
esis, it will be necessary to perform a longitudinal neuropa-
thology analysis of the brain regions affected in MJD, to
Fig. 8 17-DMAG treatment
reduced the levels of human
ataxin-3 and the aggregate load in
CMVMJD135 mice brain. (A)
Neuronal inclusions were counted
in the pontine nuclei of 30-week-
old animals treated with vehicle
or 17-DMAG (n=3 for each
condition). Four slides of each
animal were used for the analysis.
(B) qRT-PCR analysis of human
ATXN3 mRNA expression levels
(n=4). (C) Anti-ataxin-3 western-
blot (rabbit anti-MJD1.1) of 30-
week-old CMVMJD135 mice,
either vehicle or treated with 17-
DMAG (n=4 for each condition),
were performed in the brainstem.
Mutant human ataxin-3
has a molecular weight of
approximately 80 kDa. Values are
presented as mean ± SEM;
*p<0.05, **p<0.01, ***p<0.001
Fig. 7 17-DMAG improves motor coordination of CMVMJD135 mice.
(A) Motor swimming test was performed at 16, 22, 24 and 30 weeks of
age (n=10–12 animals for each tested group) and the mean latency of the
third day test was analyzed. Transgenic mice displayed swimming
impairments, given by a significant increase in the time spent to swim
across 60 cm distance, and 17-DMAG treatment improved their
performance. (B) Rotarod test was performed at 22 and 30 weeks of
age (n=10–12 for each tested group) to evaluate motor coordination at
constant speed in the rod (8, 15, 20, 24 and 31 rpm). 17-DMAG treatment
was able to rescue this phenotype at 22 weeks of age. (C) Balance beam
test was performed at 14, 16, 22, 24 and 30 weeks of age (n=10–12 for
each tested group. 17-DMAG treatment significantly improved balance
deficits at 22 and 24 weeks of age. Values are presented as mean ± SEM.
(D) Quantitative analysis of the percentage of animals showing foot-
dragging. 17-DMAG treatment delays the onset and progression of this
symptom. *p<0.05, **p<0.01, ***p<0.001
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establish correlations between the phenotype here defined and
the neurodegeneration pattern.
An important feature of MJD, as well as of other polyQ
diseases, is the presence of neuronal inclusions containing the
mutant protein. Our previous results have shown the presence
of motor symptoms in a transgenic mouse model of MJD in
the absence of intranuclear inclusions, suggesting that these
are not essential for disease manifestation [31]. However, the
nature and relevance of intermediate species of the aggrega-
tion process remains to be elucidated in this disorder. In this
new transgenic mouse, intranuclear inclusions were present in
the cells of affected brain regions, such as the pontine and
deep cerebellar nuclei, but also in regions that are spared, such
as the anterior olfactory nuclei and ventral tenia tecta. This is
concordant with what is seen in human MJD patients, where
neurodegeneration was not clearly correlated with the occur-
rence of ataxin-3 immunopositive inclusions [39]. Moreover,
neuronal inclusions were observed already at 20 but not at 16
weeks of age, when several motor symptoms were already
clearly present. This is in agreement with previous results
obtained in other transgenic mouse models of MJD, in which
symptoms appear before the detection of the inclusions [40].
Although the role of intranuclear inclusions, the end-
product of the aggregation process in MJD pathogenesis,
remains to be clarified, the presence of this pathological
hallmark of disease in our model indicates that it successfully
replicates the full aggregation process that happens in humans.
The combination of clinical and neuropathologic features of
Fig. 9 17-DMAG is able to induce autophagy in CMVMJD135 animals.
ELISA assays, western blots and qRT-PCR analysis of HSR and autoph-
agy markers were performed in the brainstem or forebrain of 16-, 20- or
30-week-old wt and CMVMJD135 mice (n=4–5) treated with vehicle or
17-DMAG (25 mg/kg), 12 hours after the last treatment. (A) Hsp70,
Hsp40 mRNA expression levels were normalized for the housekeeping
gene HPRT. (B) ELISA assay for Hsp70 quantification. Anti- Beclin-1
(C) and anti-LC3 (D) western-blots. LC3-II was normalized both for
tubulin and LC3-I; Beclin-1 was normalized for tubulin. Values are
presented as mean ± SEM; *p<0.05, **p<0.01, ***p<0.001
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CMVMJD135 mice prompted us to start pre-clinical trials
using different compounds, targeting different potential path-
ogenic mechanisms for MJD.
The chaperone machinery has the potential to neutralize the
toxicity caused by misfolded and aggregated proteins, making
the activation of molecular chaperones an attractive therapeu-
tic strategy [21, 41]. Treatment of CMVMJD135 mice with
17-DMAG markedly improved motor performance, given by
the results in the motor swimming, rotarod and beam balance
tests, reduced the expression levels of human ataxin-3 at
protein level and reduced the nuclear aggregate load in the
pontine nuclei. Regarding neuropathology, 17-DMAG also
led to a visible amelioration in cell morphology in affected
brain areas, such as the pontine nuclei, at 16 and 30 weeks of
age. Intriguingly, however, 17-DMAG had no beneficial ef-
fect in other neurological symptoms, for instance, limb weak-
ness, tremor and abnormal reflexes, and the beneficial effects
of 17-DMAG treatment were not maintained throughout dis-
ease progression. At 30 weeks of age, CMVMJD135 mice
treated with 17-DMAG started to present MJD symptoms
similar to those of mice treated with saline. Data from preclin-
ical toxicity studies for 17-DMAG in animal models have
recently become available [33], leading us to believe that it
is possible to further increase 17-DMAG dose (higher than
25mg/kg) while keeping outside its toxicity range; this should
be tested in future studies.
In our study, and in spite of the therapeutic effects ob-
served, the chronic administration of 17-DMAG failed to
induce the HSR in CMVMJD135 mice, particularly at later
stages of the disease. This is in agreement with what was
recently described in a Huntington’s disease mouse model
treated with an Hsp90 inhibitor [42]. These authors tested
the effectiveness of HSF-1 dissociation from the Hsp90 com-
plex, its translocation to the nucleus and consequent
hyperphosphorylation, features interfering with HSF-1
trimerization and its ability to induce HS gene expression
[43], and concluded that all those processes were occurring
normally upon treatment, suggesting that the problem was at
the level of transcriptional activation of HSF1 targets due to
excessive chromatin condensation. A similar phenomenon
appears to be taking place in CMVMJD135 mice.
Since it was previously shown that 17-AAG and its ana-
logue used in this study—17-DMAG—are able to activate the
autophagy process in different model systems [35–37], and
given that our results suggested degradation of ataxin-3 was
occurring, we assessed known autophagy markers in 17-
DMAG-treated animals. Our results suggest that autophagy
is activated by the drug specifically in diseased animals. This
is confirmed by an increase in the protein levels of Beclin-1
and LC3-II , detected only in 17-DMAG-treated
CMVMJD135 mice. Although we could not observe an in-
duction of HS genes at the age tested (20 and 30 weeks of
age), this induction might still happen earlier in life, being no
longer seen in later disease stages, when autophagy starts
taking place as a compensatory mechanism. In addition to
improving the major symptoms of disease, 17-DMAG re-
duced mutant protein levels and aggregate load in
CMVMJD135 mice, which is a good additional proof of its
beneficial effects. 17-DMAG is currently in Phase I of clinical
trials for advanced solid tumors (www.clinicaltrials.gov), to
t e s t d o s a g e , t o x i c i t y, p h a rma co k i n e t i c s a n d
pharmacodynamics. So far, the most frequently observed
collateral effects of this compound were fatigue, nausea,
diarrhea and headache [44]. Although the effects of
continuous activation of HSF-1 are not well understood, and
it was suggested to be detrimental in some situations [45], our
data show that 17-DMAG is a promising compound and
Hsp90 an interesting molecular target for MJD therapy. There
is a need to better understand the impairment of the HSR
during aging in mice (since this study is not easy to perform
in humans) which will help in the development of new drugs
that can act synergistically with 17-DMAG in the improve-
ment of proteostasis.
Materials and Methods
Generation of Transgenic Mice, Breeding, Genotyping, CAG
Repeat Sizing and Mouse Maintenance
To generate transgenic MJD mice, we converted the ATXN3a
cDNA variant carrying a repeat tract ((CAG)2CAAAAGCA
GCAA(CAG)124), coding for 130 glutamines (plasmid
pF25B3.3::AT3Q130::YFP) in the ATXN3c variant [18] into
the pCMV vector (Fig. 1A). This plasmid, designated
pCMVAT3Q135_1.5, was linearized by total digestion with
PaeI (Fermentas), the fragment of interest (3150 bp) was then
purified from an agarose gel using the QiaQuick gel extraction
system (Qiagen, Hamburg, Germany) and microinjected into
fertilizedmurine oocytes of the C57Bl/6 mouse strain (QTRN,
Canada). To establish the lineage CMVMJD135, founder C
was bred with C57Bl/6 females and the hemizygous progeny
were bred with littermate wt animals to generate the experi-
mental groups. DNA extraction, animal genotyping, transgene
copy number and CAG repeat size analyses were performed
as previously described [31].
All animal procedures were conducted in accordance with
European regulations (European Union Directive 86/609/
EEC). The animals were anesthetized with a mixture of keta-
mine hydrochloride (150 mg/kg) plus medetomidine
(0.3 mg/kg). Animal facilities and the people directly involved
in animal experiments (ASF, SDS, ANC) were certified by the
Portuguese regulatory entity—Direcção Geral de Veterinária.
All of the protocols performed were approved by the joint
Animal Ethics Committee of the Life and Health Sciences
Research Institute, University of Minho, and the Institute for
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Molecular and Cell Biology, University of Porto. Health mon-
itoring was performed according to FELASA guidelines [46],
confirming the Specified Pathogen Free health status of sen-
tinel animals maintained in the same animal room.
Behavioral Analysis
CMVMJD135 phenotypic characterization was performed
during the diurnal period in groups of five animals per cage
including CMVMJD135 hemizygous transgenic mice and wt
littermates (n=11–15 per genotype and gender). The mean
repeat size (±SD) for all mice used was (133±1). Animals
were evaluated monthly in the rotarod [31] (beginning at 4
weeks of age until 40 weeks of age), by the modified SHIRPA
protocol [31] (at 7, 19 and 40 weeks of age), using the balance
beam test [47] (at 10 and 22 weeks of age) and the motor
swimming test [47] (between 22–25 and 40 weeks of age).
Rotarod tests and footprinting pattern were performed as
previously described [31] as was the SHIRPA protocol, with
the addition of the hanging wire grip test. To evaluate the
severity of foot-dragging through age the footprinting patern
of CMVMJD135 (n=10) and wt controls (n=7) was
classified at each time point considering six consecutive steps
(0=absent/mild, up to three steps; 1=moderate, more than
three steps out of six; 2=severe, all steps out of six).
Hanging Wire Grip Test Each mouse was placed on a wire
cage top, which was slowly inverted and suspended at ap-
proximately 30 cm to the floor. The time it took each mouse to
fall from the cage top was recorded. Any mouse still gripping
the cage top after 60 seconds was removed.
Balance Beam Test Motor coordination and balance of mice
were assessed by measuring the ability of the mice to traverse
a graded series of narrow beams to reach an enclosed safety
platform as previously described [47]. The beams consisted of
long strips of PVC (1 m) with a 27- and 11-square cross-
section or a 28-, 15-, or 10-mm round diameter. During
training, mice were placed at the start of the 11-mm square
beam and trained over 3 days (3 trials per day) to traverse the
beam to the safe platform.
Motor swimming test [47] and Morris water maze were
performed as previously described [48, 49].
Western Blot
Protein isolation from mouse tissues and western blot were
performed as previously described [31] homogenized in cold
RIPA buffer and a mixture of protease inhibitors (Complete;
Roche). The blots were blocked overnight at 4 °C with the
primary Ab: rabbit anti-ataxin-3 serum (kindly provided by
Dr. Henry Paulson) (1:10000); mouse anti-Hsp70 (1:2000
StressGene), rabbit anti-LC3 (1:500 Cell Signaling), rabbit
anti-Beclin1 (1:1000 Cell signaling) and mouse anti-alpha-
tubulin (1:100, DSHB). Band quantification was performed
using ImageJ software according to the manufacturer’s in-
structions using alpha-tubulin as the loading control.
qRTPCR
Total RNA was isolated from CMVMJD135 mice tissues
using TRIZOL (Invitrogen, Calrsbad, CA, USA) according
to the manufacturer’s protocol. First-strand cDNA, synthe-
sized using oligo-dT (Bio-rad), was amplified by quantitative
reverse-transcriptase PCR (qRT-PCR) as previously described
[31]. Human and mouse ataxin-3 primers were used for trans-
gene expression quantification [31]: HSP40 (F: 5’CGCCGG
ACGGGTATATAGAG3’; R: 5’GGCCCAGCGTCTGATA
GTAG3’), HSP70 (F: 5’CCAACGCTGTCACTCAAACC
3’; R: 5’GCCCTTGTCCAGAACTCTCC3’) and LC3 (F:
5’TTCTTCCTCCTGGTGAATGG3’; R: 5’GTGGGTGCCT
ACGTTCTCAT3’).
Neuropathology and Immunohistochemistry
Transgenic and wt littermate mice were deeply anesthetized
and transcardially perfused with PBS followed by 4 % para-
formaldehyde (PFA) in PBS. Brains were postfixed overnight
in fixative solution and embedded in paraffin. Slides with
4-μm-thick paraffin sections were stained with cresyl violet
or processed for immunohistochemistry with rabbit GFAPAb
(DAKO Corporation, Carpinteria, CA) (1:500) or rabbit anti-
MJD1.1 [50] (1:40) or anti-ubiquitin (1:500) [31]. Ataxin-3
positive inclusions in the pontine nuclei of 30 weeks old
animals either vehicle or 17-DMAG treated (n=3–4 for each
condition, three slides per animal) were quantified and normal-
ized for total area using the Olympus BX 51 stereological
microscope and the Visiopharma integrator system software.
Stereological Analysis Neuronal number and volume were
obtained by systematic random sampling in pontine nuclei
from Bregma level −3.80 mm through 4.60 mm; substantia
nigra from Bregma level −2.46 mm through 4.04 mm; locus
coeruleus from Bregma level −5.34 mm through 5.80 mm and
dentate nuclei from Bregma level −5.68 mm thourh 6.36,
according to the Paxinos and Franklin mouse brain atlas of
2001. Every second section containing the region of interest
was selected to obtain a sample in a systematic uniform and
randommanner (section sampling fraction; ssf = 0.5). Volume
estimation was obtained according to Cavalieri’s principle
[51]. Each known area was multiplied by the represented
thickness (30 μm x 2 sections). Average cell numbers were
estimated using the optical fractionator method [52]. The area
(a) of the counting frame was 400 μm2 (20 μm x 20 μm), the
area sampling fraction (asf) = a (frame)/ a (step length) was
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0.004. The height (h: 15 μm) of the optical dissector was
equivalent to the thickness of the section (t: 30 μm).
The measurements were performed using The Visiopharm
Integrator System, version 2.12.3.0 and a camera (Pixelink PL-
A622) attached to a motorized microscope (Olympus BX51).
17-DMAG Dose Determination
Wt animals were injected with 17-DMAG (InvivoGen) at
different concentrations (5, 10 and 25 mg/kg, n=4 per dose)
three times per week on alternate days, and 12 hours after the
last injection the animals were sacrificed. Another set of
animals (n=4) was injected with vehicle (saline NaCl 0,9 %)
and sacrificed at the same time. The protein levels of Hsp70
were measured by western blot in the muscle and in the brain.
Determination of Blood/Plasma Ratio to Estimate 17-DMAG
brain exposure
A total of six C57Bl/6 mice at approximately 6 months of age
were used, in which two were injected intraperitoneally three
times in a week with saline—0.9 % NaCl and four animals
with 17-DMAG 25 mg/kg. Animals were anesthetized 1 hour
post-injection and the blood was removed from the inferior
vena cava, and after perfusion with PBS brains were dissected,
weighted and immediately frozen at −80ºC. Brain tissue was
homogenized in acetonitrile:H20 (4:1 v/v). After centrifuga-
tion, plasma and brain supernatants were harvested and sam-
ples were frozen at −80 °C until bioanalysis. Brain and plasma
samples were analysed for content of drug by use of
UltraPerformance LC® (UPLC®) chromatography followed
by tandem-MS (MS/MS) detection.
Hsp70 ELISA Assay
An Hsp70 ELISA kit (ADI-EKS-700B from ENZO life sci-
ences, UK) was used to measure the Hsp70 concentration in
brain tissue frommice. The analysis was carried out according
to the manufacturer’s instructions. Briefly, forebrain tissue
protein extracts were obtained as described above and extrac-
tion reagent (ELISA kit) with phosphostop and protease in-
hibitor cocktail was added. The homogenate was spinned
down at 20,000 g for 10 min and the supernantant was kept
at −80 °C until analysis. The protein concentration was deter-
mined using a standard BCAProtein assay (Thermo scientific,
Denmark), and upon ELISA analysis, 100 μg of protein was
analysed per well according to the standard protocol. The
developed plates were measured with a Spectramax 340PC
(Molecular Devices Inc., USA) at 450 nm (reference 540 nm).
Hsp70 concentration was calculated based on the standard
curve and expressed as ng of Hsp70 per ml.
17-DMAG Treatment and Behavioral Assessment
CMVMJD135 and littermate mice (n=10−12 for each group)
were intraperitoneally injected three times a week since 5
weeks of age (one week before the onset of symptoms) with
17-DMAG at 25 mg/kg (for a mean mouse weight of 25 g) or
with a 0.9 % saline solution. The animals were evaluated every
two weeks in the balance beam test and using the SHIRPA
protocol since 6 weeks of age. Foot-dragging was evaluated as
described above and at the age of 16, 22, 24 and 30 weeks the
animals were also tested in the rotarod and in the motor swim-
ming test. Behavior analysis methods were described above.
Statistical Analysis
Power analysis was used to determine the sample size [53].
Considering the different variables under study, such as weight,
time held in the hanging wire, rotarod and swimming latency,
assuming a power of 0.8 and a significance level of 0.05,
different required sample sizes were obtained, depending on
the specified smallest detectable difference and the variability
within the four populations under study (wt vehicle, wt 17-
DMAG, tg vehicle and tg 17-DMAG). Based on these calcu-
lations and bearing in mind that as the age of the animals
increases also the mean differences increase and, possibly, the
standard deviations, a sample size ranging between five and ten
animals was obtained and, therefore, a sample of ten animals
was chosen. Sample size calculations of each behavioral test
were also assessed assuming a power of 0.8 and a significance
level of 0.05 (Supplementary Table). The effect size was cal-
culated taking into account an improvement of 50 %, using
mean and standard deviation values previously obtained for
transgenic and control groups for the different behavioral tests.
Behavioral data were analyzed by the non-parametric
Mann–Whitney U-test when variables were non-continuous
or when a continuous variable did not present a normal
distribution (Kolmogorov-Smirnov (K-S) test p<0.05). Con-
tinuous variables with normal distributions (K-S test p>0.05)
were analyzed with the Student’s t-test and two-way ANOVA
(factors: genotype and age for basal behavioral characteriza-
tion of the CMVMJD135 mice; factors: genotype and treat-
ment in the 17-DMAG preclinical trial). For the motor swim-
ming test, repeated-measures ANOVAwas performed consid-
ering two factors: genotype and treatment. All statistical anal-
yses were performed using SPSS 22.0 (SPSS Inc., Chi-
cago, IL). A critical value for significance of two-tailed
p<0.05 was used throughout the study.
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